COMPOSITION:

Each LuciAsc tablet contains: 43.24mg Asciminib HCL equivalent to Asciminib ………… 40mg

INDICATION:  

LuciAsc is a kinase inhibitor indicated for the treatment of adult patients with:

· Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs).

· Ph+ CML in CP Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) with the T315I mutation.

DOSAGE AND USE:

· Recommended Dosage in Ph+ CML in CP: 80 mg orally once daily or 40 mg twice daily.

· Recommended Dosage in Ph+ CML in CP with the T315I Mutation: 200 mg orally twice daily.

Avoid food for at least 2 hours before and 1 hour after taking LuciAsc. Tablet should be swallowed whole & not chewed or crushed.

STORAGE:

in a dry place and store at 20°C to 25°C.

MANUFACTURED AND MARKETED BY: 

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING:

Keep medicine out of reach of Children. Do not administered LuciAsc in Pregnancy and Lactation patient treatment.